Ixekizumab for treatment of psoriasis

Beatrice Dyring-Andersen; Lone Skov; Claus Zachariae

doi:10.1586/1744666X.2015.1023295

Ixekizumab for treatment of psoriasis

Beatrice Dyring-Andersen, Lone Skov, Claus Zachariae

6 Citationer (Scopus)

Abstract

Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

Originalsprog	Engelsk
Tidsskrift	Expert Review of Clinical Immunology
Vol/bind	11
Udgave nummer	4
Sider (fra-til)	435-42
Antal sider	8
ISSN	1744-666X
DOI	https://doi.org/10.1586/1744666X.2015.1023295
Status	Udgivet - 1 apr. 2015

Adgang til dokumentet

10.1586/1744666X.2015.1023295

Citationsformater

@article{6ee9cbf738b04d51be28c5ffa77bf10e,

title = "Ixekizumab for treatment of psoriasis",

abstract = "Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.",

keywords = "Animals, Antibodies, Monoclonal, Humanized, Clinical Trials as Topic, Humans, Interleukin-17, Molecular Targeted Therapy, Protein Binding, Psoriasis, Receptors, Interleukin-17, Skin",

author = "Beatrice Dyring-Andersen and Lone Skov and Claus Zachariae",

year = "2015",

month = apr,

day = "1",

doi = "10.1586/1744666X.2015.1023295",

language = "English",

volume = "11",

pages = "435--42",

journal = "Expert Review of Clinical Immunology",

issn = "1744-666X",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Ixekizumab for treatment of psoriasis

AU - Dyring-Andersen, Beatrice

AU - Skov, Lone

AU - Zachariae, Claus

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

AB - Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

KW - Animals

KW - Antibodies, Monoclonal, Humanized

KW - Clinical Trials as Topic

KW - Humans

KW - Interleukin-17

KW - Molecular Targeted Therapy

KW - Protein Binding

KW - Psoriasis

KW - Receptors, Interleukin-17

KW - Skin

U2 - 10.1586/1744666X.2015.1023295

DO - 10.1586/1744666X.2015.1023295

M3 - Journal article

C2 - 25748485

SN - 1744-666X

VL - 11

SP - 435

EP - 442

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

IS - 4

ER -

Ixekizumab for treatment of psoriasis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater